aspirin has been researched along with Neutropenia in 21 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ticlopidine is an antiplatelet agent that has been proven efficacious in preventing vascular events in patients with a history of vasculopathy." | 5.30 | Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. ( Armstrong, PW; Brown, NE; Gill, S; Majumdar, S, 1997) |
| " Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lower frequency of other side effects make it a safe alternative to ticlopidine." | 5.09 | Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. ( Collins, M; Colombo, A; Iyer, S; Kreps, E; Maida, R; Moses, JW; Moussa, I; Oetgen, M; Roubin, G; Wang, X, 1999) |
| "Compared with aspirin, clopidogrel reduced the combined risk of ischaemic stroke, myocardial infarction or vascular death by 8." | 5.09 | Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999) |
| "The significance of neutropenia in Kawasaki disease (KD) has not been fully elucidated as yet." | 2.74 | Neutropenia in the acute phase of Kawasaki disease and prevention of coronary artery aneurysm. ( Hamaoka, K; Ito, H; Kiyosawa, N; Onouchi, Z; Ozawa, S; Sakata, K, 2009) |
| "048), and the frequency of adverse events was not significantly different between the two treatment groups." | 2.67 | The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. ( Weisberg, LA, 1993) |
| "Ticlopidine has not been formally compared with aspirin in patients with a completed stroke." | 2.67 | Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. ( Harbison, JW, 1992) |
| "Ticlopidine is an antiplatelet agent that has been proven efficacious in preventing vascular events in patients with a history of vasculopathy." | 1.30 | Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. ( Armstrong, PW; Brown, NE; Gill, S; Majumdar, S, 1997) |
| "Aspirin treatment in combination with neutropenia produced a 50% reduction in whole blood platelet aggregation, resulted in a significant inhibition of platelet deposition to deeply injured arteries, and decreased vasoconstriction by 66% to 15." | 1.29 | Neutrophil implications in platelet deposition and vasoconstriction after deep arterial injury by angioplasty in pigs. ( Lacoste, LL; Lam, JY; Merhi, Y, 1994) |
| "Pretreatment with aspirin (10 mg/kg) protected the sheep against the pulmonary vascular response to 20 micrograms of PAF and blocked completely the thromboxane synthesis." | 1.27 | Effects of L-652,731, a platelet-activating factor (PAF) receptor antagonist, on PAF- and complement-induced pulmonary hypertension in sheep. ( McDonald, JW; Smallbone, BW; Taylor, NE, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (28.57) | 18.7374 |
| 1990's | 12 (57.14) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Onouchi, Z | 1 |
| Hamaoka, K | 1 |
| Ozawa, S | 1 |
| Sakata, K | 1 |
| Kiyosawa, N | 1 |
| Ito, H | 1 |
| Wallace, JL | 1 |
| Zamuner, SR | 1 |
| McKnight, W | 1 |
| Dicay, M | 1 |
| Mencarelli, A | 1 |
| del Soldato, P | 1 |
| Fiorucci, S | 1 |
| Goyan, JE | 1 |
| Merhi, Y | 1 |
| Lacoste, LL | 1 |
| Lam, JY | 1 |
| Oster, G | 1 |
| Huse, DM | 1 |
| Lacey, MJ | 1 |
| Epstein, AM | 1 |
| Weisberg, LA | 1 |
| Stroncek, DF | 1 |
| Clay, ME | 1 |
| Smith, J | 1 |
| Ilstrup, S | 1 |
| Oldham, F | 1 |
| McCullough, J | 1 |
| Haushofer, A | 1 |
| Halbmayer, WM | 1 |
| Prachar, H | 1 |
| Neumann, FJ | 1 |
| Hall, D | 1 |
| Schömig, A | 1 |
| Gill, S | 1 |
| Majumdar, S | 1 |
| Brown, NE | 1 |
| Armstrong, PW | 1 |
| Moussa, I | 1 |
| Oetgen, M | 1 |
| Roubin, G | 1 |
| Colombo, A | 1 |
| Wang, X | 1 |
| Iyer, S | 1 |
| Maida, R | 1 |
| Collins, M | 1 |
| Kreps, E | 1 |
| Moses, JW | 1 |
| Harker, LA | 1 |
| Boissel, JP | 1 |
| Pilgrim, AJ | 1 |
| Gent, M | 1 |
| Diener, HC | 1 |
| Ekert, H | 1 |
| Waters, KD | 1 |
| Dawson, AA | 1 |
| Harbison, JW | 1 |
| Lee, M | 1 |
| Aldred, K | 1 |
| Lee, E | 1 |
| Feldman, M | 1 |
| FitzGerald, GA | 1 |
| Cunningham, FG | 1 |
| Gant, NF | 1 |
| Smallbone, BW | 1 |
| Taylor, NE | 1 |
| McDonald, JW | 1 |
| Merz, B | 1 |
1 review available for aspirin and Neutropenia
| Article | Year |
|---|---|
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog | 2000 |
6 trials available for aspirin and Neutropenia
| Article | Year |
|---|---|
Neutropenia in the acute phase of Kawasaki disease and prevention of coronary artery aneurysm.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Aneurysm; Humans; Immunoglobulins, Intrav | 2009 |
The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study.
Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Double-Blind Method; Female; Follow-Up Stu | 1993 |
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Diarrhea; D | 1999 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest | 1999 |
Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Diarrhea; Double-Blind Method; Female; Humans; Male; Midd | 1992 |
Ticlopidine in unstable angina. A more expensive aspirin?
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Cost-Benefit Analysis; Cycloox | 1990 |
14 other studies available for aspirin and Neutropenia
| Article | Year |
|---|---|
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi | 2004 |
Ticlopidine: quo vadis? Adverse reactions in man.
Topics: Anticoagulants; Aspirin; Diarrhea; Humans; Neutropenia; Product Surveillance, Postmarketing; Thiophe | 1984 |
Neutrophil implications in platelet deposition and vasoconstriction after deep arterial injury by angioplasty in pigs.
Topics: Angioplasty, Balloon; Animals; Aspirin; Carotid Arteries; Carotid Artery Injuries; Neutropenia; Neut | 1994 |
Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Cohort Studies; Cost-Benefit Analysis; Decision Support Te | 1994 |
Changes in blood counts after the administration of granulocyte-colony-stimulating factor and the collection of peripheral blood stem cells from healthy donors.
Topics: Adult; Aspirin; Contraindications; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Fac | 1996 |
Neutropenia with ticlopidine plus aspirin.
Topics: Agranulocytosis; Aspirin; Coronary Disease; Humans; Monitoring, Physiologic; Neutropenia; Platelet A | 1997 |
Neutropenia with ticlopidine plus aspirin.
Topics: Aspirin; Chemoprevention; Coronary Thrombosis; Coronary Vessels; Drug Combinations; Fibrinolytic Age | 1997 |
Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Fatal Outcome; Female; Humans; Middle Aged; Neutr | 1997 |
Hematologic emergencies in children.
Topics: Acute Disease; Acute Kidney Injury; Adolescent; Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Asp | 1978 |
Drug-induced haematological disease.
Topics: Anemia; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Aspirin; Bone Marrow Diseases; Hemato | 1979 |
Aspirin-induced acute gastric mucosal injury is a neutrophil-dependent process in rats.
Topics: Acute Disease; Animals; Aspirin; Blood Cell Count; Eicosanoids; Gastric Mucosa; Immune Sera; Leucovo | 1992 |
Prevention of preeclampsia--a reality?
Topics: Aspirin; Female; Humans; Infant, Newborn; Neutropenia; Pre-Eclampsia; Pregnancy | 1989 |
Effects of L-652,731, a platelet-activating factor (PAF) receptor antagonist, on PAF- and complement-induced pulmonary hypertension in sheep.
Topics: Animals; Aspirin; Complement Activation; Complement System Proteins; Dose-Response Relationship, Dru | 1987 |
Large trial finds ticlopidine superior to aspirin in preventing stroke.
Topics: Aspirin; Cerebrovascular Disorders; Female; Follow-Up Studies; Humans; Male; Neutropenia; Random All | 1989 |